Table 1 Clinical features between high and low expressions of P4HB for prostate cancer patients in the TCGA database
Characteristics | P4HB expression | P value | |
|---|---|---|---|
Low | High | ||
Sample | 215 | 215 | Â |
Age, median (IQR) | 60 (55, 65) | 62 (57, 67) | 0.009 |
Gleason score, n (%) |  |  |  < 0.001 |
 GS6 | 24 (5.6%) | 15 (3.5%) |  |
 GS7 | 122 (28.4%) | 84 (19.5%) |  |
 GS8 | 27 (6.3%) | 32 (7.4%) |  |
 GS9 | 42 (9.8%) | 84 (19.5%) |  |
T stage, n (%) | Â | Â | 0.002 |
 T2 | 92 (21.7%) | 63 (14.9%) |  |
 T3 | 118 (27.8%) | 143 (33.7%) |  |
 T4 | 1 (0.2%) | 7 (1.7%) |  |
Race, n (%) | Â | Â | 0.271 |
 Asian | 8 (1.9%) | 3 (0.7%) |  |
 Black or African American | 23 (5.5%) | 27 (6.5%) |  |
 White | 176 (42.3%) | 179 (43%) |  |
N stage, n (%) | Â | Â | 0.596 |
 N0 | 151 (40.3%) | 155 (41.3%) |  |
 N1 | 31 (8.3%) | 38 (10.1%) |  |
Residual tumor, n (%) | Â | Â | 0.008 |
 No | 149 (35.6%) | 124 (29.6%) |  |
 Yes | 59 (14.1%) | 87 (20.8%) |  |